Nova Steroid Pharma Co.,Ltd
Survodutide For Bodybuilding CAS:2805997-46-8

Survodutide For Bodybuilding CAS:2805997-46-8

Survodutideg is a novel compound speculated to belong to the glucagon-like peptide-1 (GLP-1) receptor agonist family, similar to pharmaceuticals like semaglutide (Ozempic) or tirzepatide (Mounjaro). While not yet mainstream in bodybuilding circles, its potential applications are gaining traction due to its dual-action mechanism targeting both GLP-1 and glucagon receptors.

Send Inquiry
Description

    Introduction to Survodutideg

    Survodutideg is a novel compound speculated to belong to the glucagon-like peptide-1 (GLP-1) receptor agonist family, similar to pharmaceuticals like semaglutide (Ozempic) or tirzepatide (Mounjaro). While not yet mainstream in bodybuilding circles, its potential applications are gaining traction due to its dual-action mechanism targeting both GLP-1 and glucagon receptors. This dual agonism may enhance metabolic efficiency, making it a candidate for fat loss and muscle preservation during cutting phases. Unlike traditional anabolic steroids or SARMs, Survodutideg operates through appetite suppression and glucose modulation, positioning it as a unique tool for physique athletes.

glp-1-bodybuilding-featured

master-bb

Features of Survodutideg

    2.1 Mechanism of Action

    Survodutideg's proposed mechanism involves:

    ●GLP-1 Receptor Activation: Slows gastric emptying, reduces appetite, and enhances insulin sensitivity.

    ●Glucagon Receptor Activation: Stimulates lipolysis (fat breakdown) and increases energy expenditure.
    This dual pathway could theoretically optimize fat loss while sparing muscle tissue, a critical advantage during caloric deficits.

    2.2 Unique Pharmacokinetics

    ●Extended Half-Life: Estimated at 120–140 hours, allowing weekly dosing.

    ●Non-Hormonal Action: Unlike steroids, it doesn't interact with androgen receptors, minimizing androgenic side effects.

    2.3 Hybrid Efficacy

    By merging the benefits of GLP-1 agonists (appetite control) and glucagon agonists (metabolic acceleration), Survodutideg may offer synergistic fat loss without drastic muscle catabolism.

Applications in Bodybuilding

    3.1 Cutting Phases

    Bodybuilders in caloric deficits often face muscle loss. Survodutideg's appetite suppression and fat oxidation could help maintain lean mass while shedding subcutaneous fat.

    3.2 Contest Preparation

    During peak week, athletes prioritize glycogen retention and vascularity. Survodutideg's glucose-stabilizing effects might enhance muscle fullness and reduce water retention.

    3.3 Post-Bulking Recovery

    After a mass-gain phase, Survodutideg could expedite the transition to a leaner physique by curbing rebound hunger and optimizing nutrient partitioning.

Benefits Over Traditional Compounds

    4.1 Reduced Muscle Wasting

    Unlike stimulants (e.g., clenbuterol) or harsh fat burners (e.g., DNP), Survodutideg may protect muscle via improved insulin sensitivity and protein synthesis support.

   4.2 Lower Risk of Side Effects

    ●No estrogenic, androgenic, or hepatotoxic effects.

    ●Minimal impact on heart rate or blood pressure compared to beta-agonists.

   4.3 Sustainable Fat Loss

    Gradual weight reduction (1–2 lbs/week) reduces metabolic adaptation and loose skin risk.

Dosage and Administration

    *Hypothetical Protocol (Based on GLP-1 Analogs):*

    ●Weeks 1–4: 0.25 mg/week (subcutaneous injection) to assess tolerance.

    ●Weeks 5–8: 0.5 mg/week.

    ●Weeks 9–12: 1.0 mg/week.
    Note: Titration mitigates gastrointestinal side effects (nausea, diarrhea).

Cycle Design

    A 12-week cycle is plausible, aligned with cutting phases:

    ●Weeks 1–12: Survodutideg (escalating dose).

    ●Supportive Supplements: Electrolytes, fiber (to counteract slowed digestion), and branched-chain amino acids (BCAAs) for muscle retention.

Half-Life and Dosing Schedule

    With a half-life of ~5–6 days, weekly injections maintain stable blood levels. Missed doses may require adjustments to avoid sudden appetite rebound.

Post-Treatment Considerations (PTC)

    8.1 Rebound Management

    ●Gradually reduce dosage over 2–3 weeks to prevent hyperphagia (overeating).

    ●Implement a reverse diet to slowly increase calories without fat regain.

    8.2 Long-Term Metabolic Health

     Monitor fasting glucose and lipid profiles, as prolonged GLP-1 use may alter pancreatic function.

 Risks and Ethical Considerations

    ●Uncharted Territory: Limited data on long-term use in healthy individuals.

    ●Legality: Not approved for bodybuilding; potential disqualification in tested competitions.

    ●Ethics: Debate over "cosmetic" use of metabolic drugs in sports.

Clinical Data

Trade names

Survodutide,BI 456906; ex-A7878

CAS

2805997-46-8

Molar mass

4231.692

Formula

C192H289N47O61

Purity

Above 98%

Apprarance

10mg/vial, 10vials/box

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-19128233885

   

QQ20240306150406                product-368-486                 product-521-245

 

Conclusion

   Survodutideg represents a paradigm shift in bodybuilding pharmacology, merging metabolic efficiency with muscle preservation. While promising, its novelty demands caution. Athletes should prioritize evidence-based strategies (nutrition, training) and reserve pharmacologic interventions for scenarios where risks are justified and medically supervised.

Hot Tags: survodutide for bodybuilding cas:2805997-46-8, China survodutide for bodybuilding cas:2805997-46-8 manufacturers, suppliers, factory

Inquiry
goTop

(0/10)

clearall